Antisoma halts Phase III Theragyn enrollment

Antisoma (EASD:ASOM) said data from a study using an HMFG-1 murine monoclonal antibody, similar to ASOM's Theragyn, showed a survival advantage favoring the control group. ASOM did not conduct the tri...